DelveInsight's, "Basal Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in
Key Takeaways from the Basal Cell Carcinoma Pipeline Report *
Stay informed about the cutting-edge advancements in Basal Cell Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Basal Cell Carcinoma Clinical Trials Assessment
Basal Cell Carcinoma Emerging Drugs *Patidegib: PellePharm
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.
Learn more about Basal Cell Carcinoma Drugs Opportunities in our groundbreaking
Basal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration *
Basal Cell Carcinoma Products have been categorized under various Molecule types such as *Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy *Product Type
Discover the latest advancements in Basal Cell Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Basal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Basal Cell Carcinoma Pipeline Report *Coverage- Global *Basal Cell Carcinoma Companies- PellePharm,
For a detailed overview of our latest research findings and future plans, read the full details of Basal Cell Carcinoma Pipeline on our website @ Basal Cell Carcinoma Emerging Drugs and Companies
Table of Content *Introduction *Executive Summary *Basal Cell Carcinoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Basal Cell Carcinoma - DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *Patidegib: PellePharm *Drug profiles in the detailed report..... *Mid Stage Products (Phase II) *IO103:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source